Positive News SentimentPositive NewsNASDAQ:ABSI Absci (ABSI) Stock Forecast, Price & News $1.38 +0.03 (+2.22%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$1.29▼$1.3850-Day Range$1.28▼$2.4152-Week Range$1.13▼$3.71Volume192,923 shsAverage Volume527,154 shsMarket Capitalization$127.94 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Absci MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside407.2% Upside$7.00 Price TargetShort InterestBearish3.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector624th out of 970 stocksCommercial Physical Research Industry11th out of 14 stocks 3.5 Analyst's Opinion Consensus RatingAbsci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Absci has a forecasted upside of 407.2% from its current price of $1.38.Amount of Analyst CoverageAbsci has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.80% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Absci has recently increased by 3.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABSI. Previous Next 2.5 News and Social Media Coverage News SentimentAbsci has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Absci this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Absci insiders have not sold or bought any company stock.Percentage Held by Insiders11.58% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.30% of the stock of Absci is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.97) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Absci (NASDAQ:ABSI) StockAbsci Corporation operates as a generative AI drug creation company in the United States. Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates. The company was founded in 2011 and is headquartered in Vancouver, Washington.Read More ABSI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABSI Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comAbsci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan CohenSeptember 20, 2023 | americanbankingnews.comAbsci (NASDAQ:ABSI) Stock Price Up 0.6%September 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 12, 2023 | bizjournals.comAbsci lays off 15% of workforce, revises 2023 financial outlookSeptember 6, 2023 | msn.comBiotech company Absci lays off 30 employees, about 15% of staffSeptember 6, 2023 | finance.yahoo.comAbsci to Host R&D Day on October 4, 2023August 16, 2023 | msn.comTruist Securities Reiterates Absci (ABSI) Buy RecommendationAugust 14, 2023 | finanznachrichten.deAbsci Corporation: Absci Reports Business Updates and Second Quarter 2023 Financial and Operating ResultsSeptember 29, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 14, 2023 | finance.yahoo.comAbsci Reports Business Updates and Second Quarter 2023 Financial and Operating ResultsAugust 14, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 34% in Absci Corporation (NASDAQ:ABSI)August 10, 2023 | bizjournals.comVancouver biotech to develop Bill Gates-funded HIV treatment with CaltechAugust 10, 2023 | finance.yahoo.comAbsci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine DevelopmentAugust 1, 2023 | finance.yahoo.comAbsci to Participate in the UBS MedTech, Tools and Genomics Summit 2023July 27, 2023 | finance.yahoo.comAbsci to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceJuly 6, 2023 | msn.comAbsci (ABSI) Price Target Decreased by 16.21% to 6.61June 15, 2023 | finance.yahoo.comAbsci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI SummitJune 7, 2023 | finance.yahoo.comShareholders in Absci (NASDAQ:ABSI) are in the red if they invested a year agoJune 6, 2023 | finance.yahoo.comAbsci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of PhilipsJune 4, 2023 | fool.comAbsci (NASDAQ: ABSI)May 16, 2023 | msn.comCredit Suisse Reiterates Absci (ABSI) Outperform RecommendationMay 16, 2023 | msn.comHC Wainwright & Co. Reiterates Absci (ABSI) Buy RecommendationMay 16, 2023 | finanznachrichten.deAbsci Corporation: Absci Reports Business Updates and First Quarter 2023 Financial and Operating ResultsMay 16, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on AbSci (ABSI)May 15, 2023 | finance.yahoo.comAbsci Reports Business Updates and First Quarter 2023 Financial and Operating ResultsMay 15, 2023 | finance.yahoo.comAbsci Corporation (ABSI) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2023 | marketwatch.comUniversity of Oxford's Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven ImmunotherapiesSee More Headlines Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Email Address ABSI Company Calendar Last Earnings8/14/2023Today9/28/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABSI CUSIPN/A CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees193Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+407.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,900,000.00 Net Margins-1,305.27% Pretax Margin-1,314.54% Return on Equity-36.62% Return on Assets-31.36% Debt Debt-to-Equity Ratio0.03 Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$5.75 million Price / Sales22.25 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book0.46Miscellaneous Outstanding Shares92,710,000Free Float81,975,000Market Cap$127.94 million OptionableNot Optionable Beta1.23 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Sean McClain (Age 33)Founder, CEO, Pres & Director Comp: $936.2kDr. Zachariah Jonasson Ph.D. (Age 50)Chief Bus. Officer, CFO & Director Comp: $98.3kDr. Sarah Korman J.D. (Age 43)Ph.D., Chief Legal Officer & Corp. Sec. Comp: $575.58kDr. Andreas Busch Ph.D. (Age 60)Chief Innovation Officer Comp: $1.56MMr. Todd Bedrick CPASr. VP & Chief Accounting OfficerMr. Alexander Khan CPAVP of Fin. & Head of Investor RelationsMr. Jack GoldChief Marketing OfficerKarin WierinckChief People OfficerMelissa Patterson Ph.D.Chief of StaffJens Plassmeier Ph.D.Sr. VP of Synthetic Biology R&DMore ExecutivesKey CompetitorsData Knights AcquisitionNASDAQ:DKDCAInotivNASDAQ:NOTVScience 37NASDAQ:SNCEMaxCyteNASDAQ:MXCTTheseus PharmaceuticalsNASDAQ:THRXView All CompetitorsInstitutional OwnershipFarther Finance Advisors LLCBought 23,350 shares on 9/12/2023Ownership: 0.493%Goldman Sachs Group Inc.Bought 7,376 shares on 8/15/2023Ownership: 0.101%Y Intercept Hong Kong LtdBought 71,162 shares on 8/15/2023Ownership: 0.077%Point72 Middle East FZEBought 32,130 shares on 8/15/2023Ownership: 0.035%Citadel Advisors LLCSold 21,100 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions ABSI Stock - Frequently Asked Questions Should I buy or sell Absci stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Absci in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABSI shares. View ABSI analyst ratings or view top-rated stocks. What is Absci's stock price forecast for 2023? 2 Wall Street analysts have issued 12-month target prices for Absci's stock. Their ABSI share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 407.2% from the stock's current price. View analysts price targets for ABSI or view top-rated stocks among Wall Street analysts. How have ABSI shares performed in 2023? Absci's stock was trading at $2.10 at the beginning of 2023. Since then, ABSI shares have decreased by 34.3% and is now trading at $1.38. View the best growth stocks for 2023 here. When is Absci's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our ABSI earnings forecast. How were Absci's earnings last quarter? Absci Co. (NASDAQ:ABSI) announced its earnings results on Monday, August, 14th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.03. The business had revenue of $3.37 million for the quarter, compared to analyst estimates of $2.59 million. Absci had a negative trailing twelve-month return on equity of 36.62% and a negative net margin of 1,305.27%. When did Absci IPO? (ABSI) raised $200 million in an IPO on Thursday, July 22nd 2021. The company issued 12,500,000 shares at $15.00-$17.00 per share. What is Absci's stock symbol? Absci trades on the NASDAQ under the ticker symbol "ABSI." Who are Absci's major shareholders? Absci's stock is owned by a number of retail and institutional investors. Top institutional investors include Casdin Capital LLC (1.48%), Platinum Investment Management Ltd. (1.41%), BlackRock Inc. (1.34%), Farther Finance Advisors LLC (0.49%), Geode Capital Management LLC (0.49%) and Renaissance Technologies LLC (0.46%). Insiders that own company stock include Karen K Mcginnis, Sarah Korman, Sean Mcclain and Todd Bedrick. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Absci's stock price today? One share of ABSI stock can currently be purchased for approximately $1.38. How much money does Absci make? Absci (NASDAQ:ABSI) has a market capitalization of $127.94 million and generates $5.75 million in revenue each year. The company earns $-104,900,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. How many employees does Absci have? The company employs 193 workers across the globe. How can I contact Absci? The official website for the company is www.absci.com. The company can be reached via phone at 360-949-1041 or via email at investors@absci.com. This page (NASDAQ:ABSI) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.